Cerebrospinal fluid neurogranin/β-site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease
AuthorKirsebom, Bjørn-Eivind; Nordengen, Kaja; Selnes, Per; Waterloo, Knut; Torsetnes, Silje Bøen; Gísladóttir, Berglind; Brix, Britta; Vanmechelen, Eugeen; Bråthen, Geir; Hessen, Erik; Aarsland, Dag; Fladby, Tormod
Methods: We compared Ng/BACE1 levels between cases with subjective cognitive decline (n = 18) and mild cognitive impairment (n 5 20) both with amyloid plaques and healthy controls (APOE-ε4+, n 5 16; APOE-ε4-, n 5 20). We performed regression analyses between cerebrospinal fluid levels, baseline hippocampal and amygdala volumes, and pertinent cognitive measures (memory, attention, Mini Mental State Examination [MMSE]) at baseline and after 2 years.
Results: Ng/BACE1 levels were elevated in both subjective cognitive decline and mild cognitive impairment compared to healthy controls. Higher Ng/BACE1 ratio was associated with lower hippocampal and amygdala volumes; lower baseline memory functions, attention, and MMSE; and significant decline in MMSE and memory function at 2-year follow-up.
Discussion: High Ng/BACE1 ratio predicts cognitive decline also in preclinical cases with amyloid plaques.